Insulin, pancreatic polypeptide, and glucagon antibodies in insulin-dependent diabetes mellitus
| Autor: | Priscilla Hollander, Joel Brodsky, Roger E. Pecoraro, Christopher M. Asplin, Jerry P. Palmer |
|---|---|
| Rok vydání: | 1981 |
| Předmět: |
Adult
medicine.medical_specialty Endocrinology Diabetes and Metabolism medicine.medical_treatment Insulin Antibodies Pancreatic Polypeptide Glucagon Antibodies Internal medicine Diabetes mellitus Internal Medicine medicine Diabetes Mellitus Pancreatic polypeptide Humans Insulin Advanced and Specialized Nursing Glycated Hemoglobin biology business.industry Middle Aged medicine.disease Somatostatin Endocrinology Metabolic control analysis biology.protein Hemoglobin Antibody business |
| Zdroj: | Diabetes care. 4(3) |
| ISSN: | 0149-5992 |
| Popis: | To assess the possible value of the use of high-purity pork insulin (HPPI) in the United States, the serum insulin (I), pancreatic polypeptide (PP), glucagon (G), and somatostatin (SRIF) antibody binding characteristics have been determined in 90 conventional insulin-treated diabetic subjects and related to their degree of metabolic control, as assessed by glycosylated hemoglobin (HbA1) concentration. All diabetic subjects had antibodies to insulin, but there was no relationship between any of the antibody binding characteristics and HbA1 level: 47% possessed PP antibodies; mean ± SEM HbA1 in these patients was 14.5 ± 0.3%, identical to those without PP antibodies (14.5 ± 0.4%); 10% had G binding antibodies with HbA1 levels of 14.6 ± 0.8%, similar to those without G antibodies. No subject possessed SRIF antibodies. This lack of correlation between antibody characteristics and metabolic control makes it unlikely that, in the majority of patients, treatment with a less immunogenic insulin (HPPI) versus conventional insulin will result in improved diabetic control. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|